Nektar Therapeutics (FRA:ITH0) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:ITH0 Nektar Therapeutics FRA:ITH0
47 GF Score
Price €55.06
GF Value €5.05
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Nektar Therapeutics Notes Receivable?

Nektar Therapeutics FRA:ITH0 +2.69% 47 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:ITH0 with a GF Score™ of 47/100 and a GF Value™ of €5.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Nektar Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Nektar Therapeutics Notes Receivable Related Terms

Nektar Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Nektar Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Notes Receivable Chart

Nektar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nektar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ITH0
47GF Score
Nektar Therapeutics FRA:ITH0
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nektar Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Nektar Therapeutics (FRA:ITH0) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Nektar Therapeutics and its competitors.
Is Nektar Therapeutics' Notes Receivable too high?
Nektar Therapeutics' current Notes Receivable is €0.00 Mil. Overall, Nektar Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' Notes Receivable compare to OCUL and PVLA?
Nektar Therapeutics' Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.05, compared to a current price of €55.06 — trading 990.3% above its estimated fair value. The current Notes Receivable is €0.00 Mil. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?

Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued. The current stock price of €55.06 is trading 990.3% above its estimated GF Value™ of €5.05. GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:ITH0:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €5.05 vs. price of €55.06 (990.3% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nektar Therapeutics Business Description

Other Exchanges NKTR:USA0UNL:UKITH0:Germany
Address 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score

Get the complete analysis for FRA:ITH0

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.06
Price
€5.05
GF Value